Quest Diagnostics 2015 Annual Report Download - page 11

Download and view the complete annual report

Please find page 11 of the 2015 Quest Diagnostics annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 129

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129

7
With these priorities in mind, during 2015 we introduced over 20 new or enhanced disease area solutions, including
those discussed below.
Table 11 - New or Enhanced Disease Area Solutions
Cardiovascular,
Metabolic and
Endocrinology
We continued to expand our CardioIQ® advanced cardiovascular testing menu with the addition
of MPO (myeloperoxidase), an inflammation marker. MPO complements the other
inflammation markers that are part of the CardioIQ® suite, providing additional insights into
disease activity in the artery wall.
We introduced a new risk panel (an advanced lipid panel with inflammation) that combines 6
important biomarkers (lipid panel, lipid subfractionation by ion mobility, apoB, Lp(a), hsCRP
and Lp-PLA2) to provide a more comprehensive risk assessment for heart attack and stroke.
We developed and released a test for Zinc transporter 8 (ZnT8) Antibody. This test is primarily
used for children and adolescents to confirm a diagnosis of type 1 diabetes.
We developed and released a test for Intact Insulin by mass spectrometry. This test is useful for
measuring fasting insulin levels and can be used to assess insulin resistance in diabetic patients.
General Health and
Wellness We made our innovative, proprietary Wellness Engine application available to our customers.
The Wellness Engine provides access to our wellness screening, reporting and incentive
management solutions and offers:
Greater customization of program elements to meet the needs of diverse populations;
Simpler, intuitive participant experience that promotes greater engagement; and
Fully integrated data, regardless of collection site or type, to provide more powerful,
actionable insights.
Infectious Diseases
and Immunology We launched automatic performance of molecular testing on all patient specimens whose
antibody screening results indicate hepatitis C virus infection, and removed standalone antibody
screening as a test option. This change eliminated the prospect that a patient may receive a
positive screening result but fail to undergo additional molecular testing, as recommended by
medical guidelines, to help confirm a diagnosis of active hepatitis C infection, the cause of
chronic hepatitis C.
We developed and introduced a test for HIV-1 RNA, Quantitative Real-Time PCR with reflex to
Coreceptor Tropism. This test may be used to determine whether a patient's viral HIV-1 load is
sufficient to perform the HIV-1 RNA tropism test.
We developed the Helicobacter pylori, Culture with Reflex to Susceptibility assay. Helicobacter
pylori has been associated with peptic ulcer disease and cancers of the gastrointestinal tract.
We developed a rapid identification test for Leptospirois, an infection caused by a waterborne
spirochete of the genus Leptospira.
QUEST DIAGNOSTICS 2015 ANNUAL REPORT ON FORM 10-K